Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer

Trial Profile

Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Niraparib (Primary)
  • Indications Lung cancer; Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors TESARO
  • Most Recent Events

    • 09 Oct 2017 Status changed from planning to recruiting.
    • 03 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top